Genomic analyses identify molecular subtypes of pancreatic cancer
MetadataShow full item record
Â© 2016 Macmillan Publishers Limited. All rights reserved.Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-Î², WNT, NOTCH, ROBO/SLIT signalling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing. Expression analysis defined 4 subtypes: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) that correlate with histopathological characteristics. Squamous tumours are enriched for TP53 and KDM6A mutations, upregulation of the TP63Î”N transcriptional network, hypermethylation of pancreatic endodermal cell-fate determining genes and have a poor prognosis. Pancreatic progenitor tumours preferentially express genes involved in early pancreatic development (FOXA2/3, PDX1 and MNX1). ADEX tumours displayed upregulation of genes that regulate networks involved in KRAS activation, exocrine (NR5A2 and RBPJL), and endocrine differentiation (NEUROD1 and NKX2-2). Immunogenic tumours contained upregulated immune networks including pathways involved in acquired immune suppression. These data infer differences in the molecular evolution of pancreatic cancer subtypes and identify opportunities for therapeutic development.
Showing items related by title, author, creator and subject.
Johns, A.; McKay, S.; Humphris, J.; Pinese, M.; Chantrill, L.; Mead, R.; Tucker, K.; Andrews, L.; Goodwin, A.; Leonard, C.; High, H.; Nones, K.; Waddell, N.; Patch, A.; Merrett, N.; Pavlakis, N.; Kassahn, K.; Samra, J.; Miller, D.; Chang, D.; Pajic, M.; Pearson, J.; Grimmond, S.; Waddell, N.; Zeps, Nikolajs; Gill, A.; Biankin, A.; Johns, A.; Gill, A.; Chang, D.; McKay, S.; Chantrill, L.; Chin, V.; Chou, A.; Humphris, J.; Pajic, M.; Steinmann, A.; Arshi, M.; Drury, A.; Froio, D.; Morgan, A.; Timpson, P.; Hermann, D.; Vennin, C.; Warren, S.; Pinese, M.; Wu, J.; Pinho, A.; Pearson, J.; Patch, A.; Nones, K.; Newell, F.; Mukhopadhyay, P.; Addala, V.; Kazakoff, S.; Holmes, O.; Leonard, C.; Wood, S.; Xu, C.; Grimmond, S.; Hofmann, O.; Wilson, P.; Christ, A.; Bruxner, T.; Samra, S.; Arena, J.; Pavlakis, N.; High, H.; Mittal, A.; Asghari, R.; Merrett, N.; Pavey, D.; Das, A.; Cosman, P.; Ismail, K.; O'Connnor, C.; Williams, D.; Spigellman, A.; Lam, W.; McLeod, D.; Nagrial, A. (2017)Background: The return of research results (RoR) remains a complex and well-debated issue. Despite the debate, actual data related to the experience of giving individual results back, and the impact these results may have ...
GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabineFerro, R.; Adamska, A.; Lattanzio, R.; Mavrommati, I.; Edling, C.; Arifin, S.; Fyffe, C.; Sala, G.; Sacchetto, L.; Chiorino, G.; De Laurenzi, V.; Piantelli, M.; Sansom, O.; Maffucci, T.; Falasca, Marco (2018)© 2018, Macmillan Publishers Limited, part of Springer Nature. The life expectancy for pancreatic cancer patients has seen no substantial changes in the last 40 years as very few and mostly just palliative treatments are ...
Ferro, R.; Falasca, Marco (2014)Pancreatic cancer is a highly aggressive tumour that is very resistant to treatments and it is rarely diagnosed early because of absence of specific symptoms. Therefore, the prognosis for this disease is very poor and it ...